Emma Bratt

Title: Emma Bratt: Innovator in Antithrombotic and Anticoagulant Research

Introduction

Emma Bratt is a notable inventor based in Molndal, Sweden. She has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds with antithrombotic and anticoagulant properties. Her work is essential for advancing medical treatments for humans and animals.

Latest Patents

Emma Bratt holds a patent for her invention titled "Derivatives of 6-{4-[4-(1H-indole-2-sulphonyl)-piperazin-1-carbonyl-phenyl]}pyradizin-3-one." This invention relates to heterocyclic derivatives that possess valuable medicinal properties. The compounds described in her patent are useful in the treatment of various conditions due to their antithrombotic and anticoagulant effects. The patent outlines the processes for preparing these derivatives and their applications in pharmaceutical compositions.

Career Highlights

Emma Bratt is currently employed at AstraZeneca AB, a leading global biopharmaceutical company. Her role involves research and development in the pharmaceutical sector, where she focuses on innovative solutions for health challenges. Her expertise and dedication have positioned her as a key player in her field.

Collaborations

Emma has collaborated with esteemed colleagues, including Yantao Chen and Kenneth Lars Granberg. These partnerships have enhanced her research efforts and contributed to the successful development of her patented compounds.

Conclusion

Emma Bratt is a pioneering inventor whose work in antithrombotic and anticoagulant research is making a significant impact in the pharmaceutical industry. Her contributions are vital for the advancement of medical treatments, showcasing her dedication to improving health outcomes.